FT011 is a first-in-class oral therapy designed to treat chronic fibrosis in multiple organs. It is currently progressing through clinical development for the treatment of scleroderma. It acts
NICE has released the final draft guidance (FDG) that suggests Brukinsa as a recommended treatment for eligible adults with untreated CLL if there is a 17p deletion or
PCI will be responsible for the formulation, packaging, and distribution of a siRNA-based investigational injectable treatment for inflammatory dermatological conditions. The organisation will carry out all these activities
Maxigesic IV, which is a combination of 1000mg paracetamol and 300mg ibuprofen solution, is given intravenously to adults for relieving mild to severe pain. It received approval for
The NDA has been submitted based data from the randomised Phase III MARCH PFIC study of LIVMARLI. A total of 93 patients with various generic PFIC subtypes including
Following this approval, Knight expects to launch Minjuvi in Brazil in Q2 2024. In July this year, Agência Nacional de Vigilância Sanitária (ANVISA) granted market authorisation under the
CHMP also recommended approval of the anti-programmed death receptor-1 (PD-1) therapy. It recommended approval of KEYTRUDA along with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for locally advanced
With this expansion and added production line, the company can now offer more plasmid material in quality and GMP grades as well as extend the mRNA supply services.
The multicentre, open-label study will evaluate the autologous fully human anti-cd19 chimeric antigen receptor (CAR) T cell therapy KYV-101 in adult scleroderma patients. Kyverna Therapeutics CEO Peter Maag
The contract was signed through TaiGen’s subsidiary company TaiGen Biotechnology. Considering the competitiveness of the pharmaceutical market as well as concerns about proprietary information, the companies did not
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.